TABLE.
Immunotherapy Clinical Trials in Advanced Urothelial Cancer
| Study | Setting | Phase | Agent(s) | Patients No. | ORR, % | PFS, mo | OS, mo |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Keynote 0525 | 1st line | 2 | Pembrolizumab | 370 | 24 | 2.0 | N/A |
|
| |||||||
| IMvigor 2106 | 1st line | 2 | Atezolizumab | 119 | 23 | 2.7 | 15.9 |
|
| |||||||
| Keynote 0457 | 2nd line | 3 | Pembrolizumab | 542 | 21.1 | 2.1 | 10.3 |
| Chemotherapy | 11.4 | 3.3 | 7.4 | ||||
|
| |||||||
| Checkmate 2758 | 2nd line | 2 | Nivolumab | 270 | 19.6 | 2.0 | 7.0 |
|
| |||||||
| IMvigor 2119 | 2nd line | 3 | Atezolizumab | 931 | 13.4 | 2.1 | 11.1 |
| Chemotherapy | 13.4 | 4.0 | 10.6 | ||||
|
| |||||||
| JAVELIN10 | 2nd line | 1 | Avelumab | 249 | 17.0 | 6.6 | 6.5 |
|
| |||||||
| NCT0169356211 | 2nd line | 1 & 2 | Durvalumab | 191 | 17.8 | 1.5 | 8.2 |
Abbreviations: FDA, US Food and Drug Administration; N/A, not applicable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.